Dr. Sweeney on Chemotherapy Versus Abiraterone for mCRPC

Christopher Sweeney, MBBS
Published: Wednesday, Dec 13, 2017



Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the role of chemotherapy versus abiraterone (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Both docetaxel and abiraterone work well, says Sweeney, but the issue is getting both drugs to achieve maximum benefit. Abiraterone is easier to tolerate since it is a hormonal therapy whereas docetaxel has a higher treatment burden.

Combining both regimens with a hormonal therapy shows similar benefit, explains Sweeney, which makes determining which regimen to give first a challenge.
 
SELECTED
LANGUAGE


Christopher Sweeney, MBBS, medical oncologist, Dana-Farber Cancer Institute, discusses the role of chemotherapy versus abiraterone (Zytiga) for patients with metastatic castration-resistant prostate cancer (mCRPC).

Both docetaxel and abiraterone work well, says Sweeney, but the issue is getting both drugs to achieve maximum benefit. Abiraterone is easier to tolerate since it is a hormonal therapy whereas docetaxel has a higher treatment burden.

Combining both regimens with a hormonal therapy shows similar benefit, explains Sweeney, which makes determining which regimen to give first a challenge.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Community Practice Connections™: 2nd Annual International Congress on Immunotherapies in Cancer™: Focus on Practice-Changing ApplicationFeb 28, 20192.0
Publication Bottom Border
Border Publication
x